Last edition
News about
FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy
Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.
Asahi Kasei expands its global pharmaceutical footprint with the acquisition of Aicuris, strengthening its pipeline in infectious diseases and advancing treatments for immunocompromised patients.
Rise in Autoimmune Diseases Reported Across Karnataka, Warn Experts
During Rheumatology Awareness Month, experts highlight increasing cases of autoimmune and rheumatology disorders in Bengaluru and smaller towns, stressing early diagnosis to prevent severe complications and delayed treatment outcomes.
AstraZeneca's Tozorakimab Hits Key Phase 3 Goal in COPD Trial
AstraZeneca reports positive Phase III MIRANDA trial results for tozorakimab in COPD, marking its third successful pivotal study and reinforcing the potential of its IL-33-targeting biologic to transform respiratory care.
BioMed X Launches First Research Team in France to Advance AI-Driven Antibody Design
BioMed X launches AI-focused antibody research team in France, aiming to accelerate development of next-generation biologic therapies for cancer and immune diseases.
NPPA directs companies to submit October 2023 pricing and turnover details for Gentamicin formulation as part of the updated price control framework under DPCO.
Morepen Laboratories Bags Zero-Observation USFDA Inspection for Fourth Time
Morepen Laboratories clears its fourth consecutive USFDA inspection at the Masulkhana facility with zero observations (NIL 483), reinforcing its CDMO strength following a INR 825 crore global manufacturing mandate.
GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom
National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.
Rusan Pharma Wins Japan PMDA GMP Nod for Two Key Plants
Rusan Pharma secures Japan PMDA GMP approval for its Ankleshwar and Dehradun facilities, covering both API and finished manufacturing dosage units.
OS Therapies files patent for immune-response biomarker linked to cancer immunotherapy
New data from the Phase IIb trial of OST-HER2 shows distinct immune signatures tied to improved survival outcomes, supporting accelerated approval discussions with global regulators.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy